177Lu-P17-087 / Five Eleven Pharma, Peking Union Medical College - LARVOL DELTA

Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study. (PubMed, Eur J Nucl Med Mol Imaging) - P1 | "[177Lu]Lu-P17-088 and [177Lu]Lu-P17-087 displayed different pharmacokinetics but excellent PSMA-targeting dose delivery in mCRPC patients. These two agents are promising RLT agents for personalized treatment of mCRPC. Further studies with increased dose and frequency of RLT are warranted to evaluate the potential therapeutic efficacy."

Journal • Metastases • P1 data • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: Peking Union Medical College Hospital | Not yet recruiting ➔ Completed

Metastases • Trial completion • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1

177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital

New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1